
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Neuropace Inc | NASDAQ:NPCE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.26 | 2.49% | 10.69 | 9.17 | 11.33 | 10.82 | 10.49 | 10.69 | 97,761 | 00:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure
NeuroPace, Inc. (“NeuroPace”) is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at approximately 4:30 p.m. Pacific time (7:30 p.m. Eastern time), and the presentation will be available through a live audio webcast. The presentation materials will be available on the Events section of the NeuroPace investor site at https://investors.neuropace.com/news-and-events/events, along with instructions for accessing the webcast.
The foregoing information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NeuroPace, Inc. | ||||||
Dated: January 15, 2025 | By: | /s/ Rebecca Kuhn | ||||
Rebecca Kuhn | ||||||
Chief Financial Officer and Vice President, Finance and Administration |
Document and Entity Information |
Jan. 15, 2025 |
---|---|
Cover [Abstract] | |
Entity Registrant Name | NeuroPace Inc |
Amendment Flag | false |
Entity Central Index Key | 0001528287 |
Document Type | 8-K |
Document Period End Date | Jan. 15, 2025 |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-40337 |
Entity Tax Identification Number | 22-3550230 |
Entity Address, Address Line One | 455 N. Bernardo Avenue |
Entity Address, City or Town | Mountain View |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94043 |
City Area Code | (650) |
Local Phone Number | 237-2700 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, $0.001 par value per share |
Trading Symbol | NPCE |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
1 Year Neuropace Chart |
1 Month Neuropace Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions